HIV-1 gp120 interacts with IgE VH3+ on the surface of human basophils and mast cells (FcΕRI+ cells), acting as a viral immunoglobulin superantigen. gp120 from different clades induces mediator release from FcΕRI+ cells. gp120 also induces IL-4 and IL-13 synthesis in human basophils. The chemokine receptors CCR3 and CXCR4, which are coreceptors of HIV-1 infection, are expressed by human FcΕRI+ cells. HIV-1 Tat protein is a potent chemoattractant for basophils and lung mast cells, interacting with CCR3. Incubation of basophils with Tat protein upregulates the surface expression of the CCR3 receptor. There is evidence that human FcΕRI+ cells could be infected in vitro by M-tropic HIV-1 strains.

1.
Marone G, Lichtenstein LM, Galli SJ (eds): Mast Cells and Basophils. San Diego, Academic Press, 2000.
2.
Marone G: Asthma: Recent advances. Immunol Today 1998;19:5–9.
3.
Patella V, Giuliano A, Bouvet J-P, Marone G: Endogenous superallergen protein Fv induces IL-4 secretion from human FcεRI+ cells through interaction with the VH3 region of IgE. J Immunol 1998;161:5647–5655.
4.
Patella V, Florio G, Petraroli A, Marone G: HIV-1 gp120 induces IL-4 and IL-13 release from human FcεRI+ cells through interaction with the VH3 region of IgE. J Immunol 2000;164:589–595.
5.
de Paulis A, Marinò I, Ciccarelli A, de Crescenzo G, Concardi M, Verga L, Arbustini E, Marone G: Human synovial mast cells. I. Ultrastructure in situ and in vitro immunologic characterization. Arthritis Rheum 1996;39:1222–1233.
6.
de Paulis A, Minopoli G, Arbustini E, de Crescenzo G, Dal Piaz F, Pucci P, Russo T, Marone G: Stem cell factor is localized in, released from, and cleaved by human mast cells. J Immunol 1999;163:2799–2808.
7.
Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ: Role for IL-3 in mast cell and basophil development and in immunity to parasites. Nature 1998;392:90–93.
8.
Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996;381:77–80.
9.
Genovese A, Bouvet JP, Florio G, Lamparter-Schummert B, Björck L, Marone G: Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E. Infect Immun 2000;68:5517–5524.
10.
Patella V, Bouvet JP, Marone G: Protein Fv produced during viral hepatitis is a novel activator of human basophils and mast cells. J Immunol 1993;151:5685–5698.
11.
Fauci AS: The AIDS epidemic – considerations for the 21st century. N Engl J Med 1999;341:1046–1050.
12.
Marone G, Austen KF, Holgate ST, Kay AB, Lichtenstein LM (eds): Asthma and Allergic Diseases. Physiology, Immunopharmacology, and Treatment. London, Academic Press, 1998.
13.
Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529–534.
14.
Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM: Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759–765.
15.
Clerici M, Shearer GM: A TH1–>TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107–111.
16.
Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL: TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8:757–762.
17.
Meyaard L, Otto SA, Keet IPM, van Lier RAW, Miedema F: Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood 1994;84:4262–4268.
18.
Meroni L, Trabattoni D, Balotta C, Riva C, Gori A, Moroni M, Villa ML, Clerici M, Galli M: Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS 1996;10:23–30.
19.
Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, Hoelzer D, Rossol R: Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997;11:1111–1118.
20.
Zou W, Dulioust A, Fior R, Durand-Gasselin I, Boue F, Galanaud P, Emilie D: Increased T-helper-type 2 cytokine production in chronic HIV infection is due to interleukin (IL)-13 rather than IL-4. AIDS 1997;11:533–535.
21.
Agarwal SK, Marshall GD Jr: In vivo alteration in type-1 and type-2 cytokine balance: A possible mechanism for elevated total IgE in HIV-infected patients. Hum Immunol 1998;59:99–105.
22.
Viganò A, Principi N, Crupi L, Onorato J, Zuccotti GV, Salvaggio A: Elevation of IgE in HIV-infected children and its correlation with the progression of disease. J Allergy Clin Immunol 1995;95:627–632.
23.
Viganò A, Principi N, Villa ML, Riva C, Crupi L, Trabattoni D, Shearer GM, Clerici M: Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr 1995;126:368–374.
24.
Koutsonikolis A, Nelson RP Jr, Fernandez-Caldas E, Brigino EN, Seleznick M, Good RA, Lockey RF: Serum total and specific IgE levels in children infected with human immunodeficiency virus. J Allergy Clin Immunol 1996;97:692–697.
25.
Secord EA, Kleiner GI, Auci DL, Smith-Norowitz T, Chice S, Finkielstein A, Nowakowski M, Fikrig S, Durkin HG: IgE against HIV proteins in clinically healthy children with HIV disease. J Allergy Clin Immunol 1996;98:979–984.
26.
Bacot BK, Paul ME, Navarro M, Abramson SL, Kline MW, Hanson IC, Rosenblatt HM, Shearer WT: Objective measures of allergic disease in children with human immunodeficiency virus infection. J Allergy Clin Immunol 1997;100:707–711.
27.
Onorato J, Esposito S, Scovena E, Morandi B, Morelli M, Pizzi M, Zisa G, Marchisio P, Principi N: Eosinophil involvement and serum IgE level in HIV-1-infected children. J Allergy Clin Immunol 1999;104:245–247.
28.
Lucey DR, Zajac RA, Melcher GP, Butzin CA, Boswell RN: Serum IgE levels in 622 persons with human immunodeficiency virus infection: IgE elevation with marked depletion of CD4+ T-cells. AIDS Res Hum Retroviruses 1990;6:427–429.
29.
Wright DN, Nelson RP Jr, Ledford DK, Fernandez-Caldas E, Trudeau WL, Lockey RF: Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol 1990;85:445–452.
30.
Miguez-Burbano MJ, Shor-Posner G, Fletcher MA, Lu Y, Moreno JN, Carcamo C, Page B, Quesada J, Sauberlich H, Baum MK: Immunoglobulin E levels in relationship to HIV-1 disease, route of infection, and vitamin E status. Allergy 1995;50:157–161.
31.
Shor-Posner G, Miguez-Burbano MJ, Lu Y, Feaster D, Fletcher MA, Sauberlich H, Baum MK: Elevated IgE level in relationship to nutritional status and immune parameters in early human immunodeficiency virus-1 disease. J Allergy Clin Immunol 1995;95:886–892.
32.
Paganelli R, Scala E, Mezzaroma I, Pinter E, D’Offizi G, Fanales-Belasio E, Rosso RM, Ansotegui IJ, Pandolfi F, Aiuti F: Immunologic aspects of hyperimmunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin Immunol 1995;95:995–1003.
33.
Rancinan C, Morlat P, Chêne G, Guez S, Baquey A, Beylot J, Salamon R: IgE serum level: A prognostic marker for AIDS in HIV-infected adults? J Allergy Clin Immunol 1998;102:329–330.
34.
Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL, Parker MM, Natanson C, Parrillo JE, Fauci AS, Pizzo PA, Masur H: Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663–671.
35.
Kaplan MH, Sadick N, McNutt NS, Meltzer M, Sarngadharan MG, Pahwa S: Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1987;16:485–506.
36.
Coopman SA, Johnson RA, Platt R, Stern RS: Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670–1674.
37.
Pedersen M, Nielsen CM, Permin H: HIV antigen-induced release of histamine from basophils from HIV infected patients. Mechanism and relation to disease progression and immunodeficiency. Allergy 1991;46:206–212.
38.
Florio G, Petraroli A, Patella V, Triggiani M, Marone G: The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. AIDS 2000;14:931–938.
39.
Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sékaly RP, Fauci AS: Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994;265:248–252.
40.
Maggi E, Mazzetti M, Ravina A, Annunziato F, De Carli M, Piccinni MP, Manetti R, Carbonari M, Pesce AM, Del Prete G, Romagnani S: Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994;265:244–248.
41.
Fakoya A, Matear PM, Filley E, Rook GAW, Stanford J, Gilson RJC, Beecham N, Weller IVD, Vyakarnam A: HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS 1997;11:1445–1452.
42.
Israël-Biet D, Labrousse F, Tourani JM, Sors H, Andrieu JM, Even P: Elevation of IgE in HIV-infected subjects: A marker of poor prognosis. J Allergy Clin Immunol 1992;89:68–75.
43.
Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS: Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 1986;233:1084–1086.
44.
Lin RY, Smith JK Jr: Hyper-IgE and human immunodeficiency virus infection. Ann Allergy 1988;61:269–272.
45.
Del Prete G, Maggi E, Parronchi P, Chretien I, Tiri A, Macchia D, Ricci M, Banchereau J, De Vries J, Romagnani S: IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988;140:4193–4198.
46.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: Interleukin-13:Central mediator of allergic asthma. Science 1998;282:2258–2261.
47.
Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261–2263.
48.
Gauchat J-F, Henchoz S, Mazzei G, Aubry J-P, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy JY: Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993;365:340–343.
49.
Schroeder JT, Howard BP, Jenkens MK, Kagey-Sobotka A, Lichtenstein LM, MacGlashan DW Jr: IL-4 secretion and histamine release by human basophils are differentially regulated by protein kinase C activation. J Leukoc Biol 1998;63:692–698.
50.
Devouassoux G, Foster B, Scott LM, Metcalfe DD, Prussin C: Frequency and characterization of antigen-specific IL-4- and IL-13-producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. J Allergy Clin Immunol 1999;104:811–819.
51.
Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britte K, Bews JPA, Hunt TC, Okayama Y, Heusser CH, Bullock GR, Church MK, Holgate ST: Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992;176:1381–1386.
52.
Okayama Y, Petit-Frére C, Kassel O, Semper A, Quint D, Tunon-de-Lara MJ, Bradding P, Holgate ST, Church MK: IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol 1995;155:1796–1808.
53.
Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells produce interleukin 13. J Exp Med 1995;181:1373–1380.
54.
Pawankar R, Okuda M, Yssel H, Okumura K, Ra C: Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the FcεRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997;99:1492–1499.
55.
Moore JP: Coreceptors: Implications for HIV pathogenesis and therapy. Science 1997;276:51–52.
56.
Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872–877.
57.
Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA: High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997;100:1137–1143.
58.
Romagnani P, de Paulis A, Beltrame C, Annunziato F, Dente V, Maggi E, Romagnani S, Marone G: Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 1999;155:1195–1204.
59.
Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA: T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267–280.
60.
Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135–1148.
61.
Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149–1158.
62.
He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997;385:645–649.
63.
Ghorpade A, Xia MQ, Hyman BT, Persidsky Y, Nukuna A, Bock P, Che M, Limoges J, Gendelman HE, Mackay CR: Role of the β-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J Virol 1998;72:3351–3361.
64.
Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648–659.
65.
Silverman GJ: B-cell superantigens. Immunol Today 1997;18:379–386.
66.
Karray S, Zouali M: Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 1997;94:1356–1360.
67.
Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, Zouali M: Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol 1998;161:6681–6688.
68.
Gelderblom HR, Hausmann EHS, Özel M, Pauli G, Koch MA: Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 1987;156:171–176.
69.
Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP, Elias CG III: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998;161:5027–5038.
70.
Marone G (ed): Human Basophils and Mast Cells: Biological Aspects. Basel, Karger, 1995.
71.
Marone G (ed): Human Basophils and Mast Cells: Clinical Aspects. Basel, Karger, 1995.
72.
Galli G, Annunziato F, Mavilia C, Romagnani P, Cosmi L, Manetti R, Pupilli C, Maggi E, Romagnani S: Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-γ on fusin/CXCR4. Eur J Immunol 1998;28:3280–3290.
73.
Penn ML, Grivel J-C, Schramm B, Goldsmith MA, Margolis L: CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999;96:663–668.
74.
Gaynor RB: Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol Immunol 1995;193:51–77.
75.
Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature 1990;345:84–86.
76.
Helland DE, Welles JL, Caputo A, Haseltine WA: Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. J Virol 1991;65:4547–4549.
77.
Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH: Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995;375:497–500.
78.
Frankel AD, Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189–1193.
79.
de Paulis A, De Palma R, Di Gioia L, Carfora M, Prevete N, Tosi G, Accolla RS, Marone G: Tat protein is an HIV-1-encoded β-chemokine homolog that promotes migration and up-regulates CCR3 expression on human FcεRI+ cells. J Immunol 2000;165:7171–7179.
80.
Li Y, Li L, Waldey R, Reddel SW, Qi JC, Archis C, Collins A, Clark E, Cooley M, Kouts S, Hassan NM, Mohammed A, Cunningham A, Wong G, Stevens RL, Krilis SA: Identification of a novel population of mast cells/basophils in human peripheral blood of allergic patients which is HIV-1 susceptible due to its surface expression of CD4, CCR5, and CXCR4 (abstract). J Allergy Clin Immunol 2000;105:586.
81.
Paiva DD, Morais JC, Pilotto J, Veloso V, Duarte F, Lenzi HL: Spectrum of morphologic changes of lymph nodes in HIV infection. Mem Inst Oswaldo Cruz 1996;91:371–379.
82.
Silver R, Silverman AJ, Vitkovic L, Lederhendler II: Mast cells in the brain: Evidence and functional significance. Trends Neurosci 1996;19:25–31.
83.
Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G: The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand SDF-1α acts as a mast cell chemotaxin. Eur J Immunol 2000;30:3614–3622.
84.
Jinquan T, Jacobi HH, Jing C, Reimert CM, Quan S, Dissing S, Poulsen LK, Skov PS: Chemokine stromal cell-derived factor 1α activates basophils by means of CXCR4. J Allergy Clin Immunol 2000;106:313–320.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.